Presenter(s): Jonathan Craig Allen, MD, FASAM, and Marc Fishman, MD
Target Audience: This activity is designed for physicians, nurses, PAs, pharmacists, social workers, peer recovery support specialists, psychologists, other behavioral health providers. This activity is accredited for physicians, nurses, PAs, pharmacists, social workers, interprofessional teams and other health professionals.
Credit designations available: Pharmacy CE Credit, AMA PRA Category 1 Credit™, AAPA Category 1 CME, Nursing Contact Hours, Social Work CE Credit, Interprofessional Continuing Education (IPCE) Credit
Webinar Description: Research indicates a lack of training and programming specific to treating and managing co-occurring opioid and stimulant use disorders, despite the increased risk of overdose bolstered by the ever-changing and adulterated drug supply. While MOUD is the gold standard of care for treating OUD, there are no FDA-approved medications for treating stimulant use disorder, though behavioral therapies like contingency management have been well-studied. These challenges highlight the need to identify promising treatment strategies to ensure individuals with co-occurring opioid and stimulant use disorders are effectively engaged in care to prevent overdose. This session will equip BH providers and organizations in this space, including Community Behavioral Health Clinics (CCBHCs), with the tools necessary to effectively engage and provide quality, team-based care and services to individuals with co-occurring opioid and stimulant use disorders in order to improve health outcomes, reduce overdose risk, and support long-term recovery.
Educational Objectives:
- Describe the broad context of co-occurring opioid and stimulant use and overdose risk in the U.S.
- Review evidence-based strategies for treating opioid use disorders and promising practices for stimulant use
- Identify evidence-based and promising strategies for treating co-occurring opioid and stimulant use disorders
- Review psychiatric co-morbidities associated with opioid and stimulant use disorders